16:47:46 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-28 Bokslutskommuniké 2024
2024-08-23 Halvårsrapport
2024-04-04 X-dag ordinarie utdelning GUBRA 0.00 DKK
2024-04-03 Årsstämma
2024-02-28 Bokslutskommuniké 2023
2023-11-01 Extra Bolagsstämma 2023
2023-08-25 Halvårsrapport

Beskrivning

LandDanmark
ListaMid Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Gubra är ett läkemedelsbolag. Bolagets verksamhet är fokuserad på de tidiga stadierna av läkemedelsutveckling. De driver huvudsakligen forskning och utveckling inom området för metabola och fibrotiska sjukdomar.. Bolagets produktportfölj innefattar ett flertal varumärken och läkemedel, och verksamheten bedrivs på global nivå, med störst närvaro inom Nordamerika och Norden. Huvudkontoret ligger i Hørsholm, Danmark.
2023-08-15 13:19:00

Today, Gubra announces preliminary Q2 and H1 2023 revenue figures for the CRO business and revises its revenue outlook for 2023 upwards, driven by strong performance in Q2 2023 as well as current trading and solid orderbook. The 2023 outlook for organic revenue growth is now expected to be 16-21% (previously around 10%). Outlook for the Discovery & Partnership business is unchanged. The organic revenue growth rate in the CRO business was 23% in the second quarter (21% in H1). The adjusted EBIT-margin in 2023 for the CRO business is still expected at around 25% due to increase in number of employees and cost recognition of a long-term incentive programs to employees implemented in Q2.

The strong revenue growth for the CRO business has been prevalent across disease categories and most notably within Liver and Kidney studies. The growth within Liver has followed the positive trend seen since Q4-2022 where positive late-stage clinical data rejuvenated the interest in this field. This has translated into increased demand for Gubra’s pre-clinical liver models. Also the increased focus in the pharmaceutical industry on obesity has led to high activity in this branch of the Gubra model-portfolio. Finally, the kidney disease category has experienced substantial growth in 2023. During the past years, Gubra has developed a large and mature kidney model catalogue, and we are experiencing traction from both big pharma to small biotech.

Upgraded outlook for 2023

Key ratioNew outlook for 2023Previous outlook for 2023
CRO Segment  
Organic revenue growth vs. 202216-21%Around 10%
EBIT-margin excl. special itemsAround 25%Around 25%
   
Discovery & Partnership Segment  
Number of new partnerships1-2 new partnerships1-2 new partnerships
Total costs* excluding special ItemsDKK 105-110 millionDKK 105-110 million
Total costs* excluding the Amylin Pipeline Asset and special ItemsDKK 85-95 millionDKK 85-95 million

* Cost of sales and operating costs

More details of the half-year results for 2023 will be published in Gubra’s half-year report for 2023 on 25 August 2023.